Slingshot members are tracking this event:

Aimmune (AIMT) Initiates Enrollment for Phase 3 PALISADE Trial Evaluating AR101 in Patients With Peanut Allergies

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 11, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Palisades Trial, Ar101, Peanut Allergies, Trial Initiation